Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344132 | 0.94 | EPHX1 (0.48) | EPHX1FAAH | |
| SCHEMBL12341213 | 0.78 | — | — | |
| SCHEMBL13488617 | 0.77 | GRIN2D (0.57) | ACHEEPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL14907251 | 0.77 | GRIN2D (0.57) | ACHEEPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL18665166 | 0.75 | KDM1A (0.42) | ACHEEPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL9116595 | 0.75 | — | — | |
| SCHEMBL18665153 | 0.74 | ACHE (0.37) | ACHEEPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3070114 | 0.71 | GRIN2D (0.61) | ACHEEPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL3070113 | 0.71 | GRIN2D (0.61) | ACHEEPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL12344217 | 0.71 | GRIN2D (0.50) | EPHX1GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | ACHE 2139/4885EPHX1 3232/4885GRIN2D 3886/4885 |
| US-20150191490-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | ACHE 1674/4885EPHX1 3718/4885GRIN2D 3608/4885 |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | ACHE 1674/4885EPHX1 3718/4885GRIN2D 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.